End-of-day quote
Korea S.E.
23:00:00 20/05/2024 BST
5-day change
1st Jan Change
13,010
KRW
-1.36%
-1.14%
-6.74%
Hana Pharm Co., Ltd's Equity Buyback announced on August 6, 2019, has expired with 87,239 shares, representing 0.54% for KRW 1,997.13 million.
The company expired its plan on February 5, 2020.
Singapore Shares Return to Green; Hyphens Pharma Rises 5% on Deal to Develop Sedation Drug in Singapore
18/05/23
MT
Hyphens Pharma to Develop, Commercialize Hana Pharm's Sedation Drug in Singapore
18/05/23
MT
Hyphens Pharma Pte. Ltd. Signs an Exclusive Sub-License and Supply Agreement with Hana Pharm Co., Ltd. to Develop and Commercialise Byfavo® 20mg in Singapore
17/05/23
CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine
12/04/22
MT
Hana Pharm Receives Market Approval for Byfavo (Remimazolam) in Procedural Sedation in South Korea
31/08/21
CI
Hana Pharm Informs PAION AG About the Launch of Byfavo™ (Remimazolam) for the Use in General Anesthesia in South Korea
07/04/21
CI
Hana Pharm Co., Ltd's Equity Buyback announced on August 19, 2019, has expired.
17/02/20
CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.
05/02/20
CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.
05/02/20
CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.
05/02/20
CI
Hana Pharm Co., Ltd's Equity Buyback announced on August 6, 2019, has expired with 87,239 shares, representing 0.54% for KRW 1,997.13 million.
04/02/20
CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on July 9, 2019.
08/01/20
CI
Hana Pharm Co., Ltd's Equity Buyback announced on July 9, 2019, has expired.
07/01/20
CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on July 26, 2019.
30/10/19
CI
Hana Pharm Co., Ltd's Equity Buyback announced on July 26, 2019, has expired with 84,312 shares, representing 0.53% for KRW 1,997.08 million.
29/10/19
CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 1,000 million worth of its shares.
19/08/19
CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.
18/08/19
CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.
06/08/19
CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.
05/08/19
CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.
26/07/19
CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.
25/07/19
CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.
09/07/19
CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.
08/07/19
CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on December 21, 2018.
20/06/19
CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on December 21, 2018.
20/06/19
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
HANA PHARM CO., LTD is a Korea-based company mainly engaged in the manufacturing and distribution of specialty pharmaceuticals. The companyâs main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The Company also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.
More about the company
1st Jan change
Capi.
-6.74% 172M +14.99% 78.65B +9.32% 8.94B -12.05% 5.16B +53.66% 4.85B +11.63% 4.19B -23.67% 2.32B +12.07% 2.29B -32.35% 2.19B +21.04% 2.19B
Specialty & Advanced Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1